Pular para o conteúdo principal
Ranking Invest

IMGN - ImmunoGen, Inc.

Segmento: HealthcareImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Análise Ranking Invest

Valuation estimado
$ 228.60 Mi
Último Balanço Atualizado: 3T2023

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 561.60 Mi

Dívida Líquida

-$ 533.42 Mi

L4T

-$ 73.07 Mi

MM4T

-50.67%

Indicadores Básicos

ROE

-13.01%

Índices de Previsibilidade

Receita Líquida

F0.63

Lucro

D0.80

Margem

D0.76

Índices de Tendência

Receita Líquida

C5.66

Lucro

E-1.93

Margem

D-0.31

Índices de Endividamento

DIV/PAT

-0.95

DIV/L4T

7.30

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.